Related Experiment Video
Updated: Jul 15, 2026

Prehospital Thrombolysis: A Manual from Berlin
Published on: November 26, 2013
Desmoteplase in the treatment of acute ischemic stroke
1Loyola University Chicago Stritch School of Medicine, Department of Neurology, Maywood, IL 60163, USA. rdafer@lumc.edu
Abstract:
Desmoteplase, developed by Paion, Forest and Lundbeck, is a novel plasminogen activator that selectively activates fibrin-bound plasminogen and is currently being investigated for the treatment of acute ischemic stroke within the time window of 3-9 h after symptom onset. Desmoteplase is believed to offer pharmacologic advantages over currently approved treatment options. To date, two published Phase II perfusion imaging-based clinical trials have reported the safety and potential efficacy of desmoteplase in ischemic stroke. Results from a recently completed Phase III trial in Europe, Asia and the USA are awaited. This article reviews the available data on desmoteplase, including discussion of its favorable features and potential benefit beyond the 3-h time window in the treatment of ischemic stroke.
Related Concept Videos
Venous Thrombosis III: Interprofessional Care
Ischemic Stroke ll: Pathophysiology
Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care
Ischemic Stroke l: Introduction
Acute Coronary Syndrome IV: Interprofessional Care
Acute Coronary Syndrome I: Introduction

